PD-1 and PD-L1 antibody block the PD-1/PD-L1 pathway, enabling upregulation of T cell activation, activating endogenous anti-tumor immune responses, and enhancing their function to kill tumor cells (Alsaab et al., 2017). Here, CD274 is linked to neoplasm.